-
摘要: 高磷血症是慢性肾脏病(CKD)、尤其是终末期肾脏病(ESRD)患者的常见并发症,可见于80％的透析患者,是继发性甲状旁腺功能亢进、肾性骨病、心血管疾病的关键因素.不同透析模式对纠正高磷血症无明显差异[1],目前临床上除限制饮食中磷的摄入和充分透析以外,主要是使用磷结合剂.碳酸钙是目前临床上最常用的磷结合剂,其长期服用可能导致高钙血症,致钙磷乘积增加,引起心血管钙化,血透患者的心血管事件明显增加.作者进行随机对照研究,比较醋酸钙与碳酸钙治疗维持性血液透析患者高磷血症的疗效,并评价其安全性.
-
-
Wallot M, Bonzel K E, Winter A. Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients [J]. Pediatric Nephrology, 2011(5):625. 杨国刚. 慢性肾衰竭患者高磷血症研究与治疗进展 [J]. 吉林医药学院学报, 2010, (31):102. Goodman W G. Importance of hyperphosphataemia in the cardio-renalaxis [J]. Nephrology Dialysis Transplantation, 2004, (Suppl 1):14. 王笑云, 谭若兰. 慢性肾脏病继发性甲状旁腺功能亢进的近代治疗 [J]. 中国血液净化, 2005(1):1. Evenepoel P, Selgas R, Caputo F. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis [J]. Nephrology Dialysis Transplantation, 2009(1):278. Achinger S G, Ayus J C. Left ventricular hypertrophy:is hyperphosphatemia among dialysis patients a risk factor [J]. Journal of the American Society of Nephrology, 2006(3):255. 刘俊. 维持性血液透析患者的降磷治疗 [J]. 实用医学杂志, 2011, (22):3998. D Almeida Filho E J, Da Cruz E A, Hoette M. Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients [J]. Sao Paulo Medical Journal:Revista Paulista de Medicina, 2009(6):179. Lezaic V, Tirmenstajn-Jankovic B, Bukvic D. Efficacy of hyperphosp hatemia control in the progression of chronic renal failure and the prevalence of cardiovascular calcification [J]. Clin Nephml, 2009(1):21.
计量
- 文章访问数: 159
- HTML全文浏览量: 70
- PDF下载量: 0
下载:
苏公网安备 32100302010246号
